COPENHAGEN, Denmark, June 22 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN) announced today Phase II AMG 714 ACR50 and ACR70 data in patients with active rheumatoid arthritis (RA) who had previously failed treatment with at least one disease modifying anti-rheumatic drug (DMARD) were presented at the European League Against Rheumatism conference (EULAR) in Amsterdam, The Netherlands. At week 14, 53% (29 of 55) of patients receiving 280 mg of AMG 714 achieved ACR50 and 25% (14 of 55) of patients achieved ACR70. In patients who received placebo, 36% (21 of 58) achieved ACR50 and 21% (12 of 58) achieved ACR70 at week 14.
These data were presented today by Dr. Iain McInnes, University of Glasgow at the EULAR conference.
AMG 714 is a fully human antibody being developed under an agreement with Amgen. Further information about the AMG 714 Phase II study can be found in Genmab’s stock exchange release dated May 16, 2006.
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US. For more information about Genmab, visit www.genmab.com.
This press release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax- EGFr(TM); HuMax-Inflam(TM); HuMax-CD20(TM); HuMax-TAC(TM); HuMax-HepC(TM) and HuMax-CD38(TM) are all trademarks of Genmab A/S. UltiMAb(R) is a trademark of Medarex, Inc.
Genmab A/S
CONTACT: Helle Husted, Director, Investor Relations, T: +45-33-44-77-30,M: +45-25-27-47-13, hth@genmab.com
Web site: http://www.genmab.com/
